Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Lymphoma
•
Myeloma
•
Internal Medicine
•
Hematology
What would your next line of therapy be for a young patient with Waldenstrom's Macroglobulinemia (MYD88 and CXCR wild type) with hyperviscosity who did not have a response to Bendamustine/Rituximab?
Related Questions
How would you manage LPL with associated AL amyloidosis?
How do you discuss harms of MGUS screening with other medical providers?
How do you utilize immunoglobulin testing to affect treatment decisions in patients with myeloma?
What is the optimal choice of therapy for a patient with Hodgkin variant of Richter's transformation from underlying CLL/SLL?
How do you approach second-line options for relapsed myeloma after front-line quadruplet therapy?
For patients diagnosed with T-cell lymphoblastic lymphoma with CNS involvement (CSF), what is your approach to the typical schedule for IT chemotherapy?
What is your preferred second line regimen for follicular lymphoma that has relapsed four years out since receiving BR?
How would you manage a patient with symptomatic low grade leukemic NHL w/o a clear diagnosis of either FL or MZL?
Does tolerance of prior BTKi therapy or specific agent used (e.g., ibrutinib, acalabrutinib) influence your starting dose of pirtobrutinib?
What clinical or logistical factors influence your choice of anti-CD38 antibody in first line treatment of Multiple Myeloma?
